Actively Recruiting
Testing Abemaciclib as an Oral Treatment for Kaposi Sarcoma in People With or Without HIV
Led by National Cancer Institute (NCI) · Updated on 2026-10-16
111
Participants Needed
1
Research Sites
13 weeks
Total Duration
AI-Summary
What This Trial Is About
Kaposi Sarcoma KS is a tumor commonly found in people with HIV but can also affect those without HIV. It usually appears on the skin but can involve lymph nodes, lungs, bones, and the gastrointestinal tract. This research aims to find a safe dose of the drug abemaciclib, which is currently used to treat some breast cancers, and to see if it can reduce KS tumors or lesions. Participants will take abemaciclib tablets orally every day in 28-day cycles, starting with a dose of 200 mg twice daily. The study includes dose adjustments and multiple participant groups, including those previously treated and untreated for KS. Treatment continues until the cancer worsens or side effects become unacceptable. Some participants who stopped the drug earlier may be able to restart it. The study involves repeated cycles with medical assessments and questionnaires. During the study, participants will have visits at the start of each cycle for tests, including physical exams, imaging, skin lesion assessments, and sample collections from skin and saliva. They will also keep a medicine diary and may have photographs taken. Follow-up visits will continue for up to two years after treatment ends to monitor safety and effectiveness. Researchers will track safety, tumor response, progression-free survival, and duration of response.
CONDITIONS
Brief Title
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Research Team
I
Irene B Ekwede, R.N.
R
Ramya M Ramaswami, M.D.
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here